Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus RETET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus RETET.
DEMECLOCYCLINE HYDROCHLORIDE vs RETET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
RETET is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors, thereby blocking estrogen-mediated signaling in target tissues.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
No standard dosing available; RETET is not a recognized therapeutic agent. Please verify drug name.
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Terminal elimination half-life 18-24 hours in healthy adults; prolonged to 30-40 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Renal: 70-80% unchanged; Fecal: 10-15%; Biliary: <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic